Allison Bratzel
Stock Analyst at Piper Sandler
(4.71)
# 170
Out of 5,044 analysts
43
Total ratings
70.59%
Success rate
22.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IOBT IO Biotech | Maintains: Overweight | $10 → $3 | $0.90 | +232.96% | 1 | Oct 22, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $52 → $51 | $29.88 | +70.68% | 4 | Sep 24, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $750 → $820 | $836.39 | -1.96% | 14 | Aug 26, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $65 | $73.57 | -11.65% | 2 | Aug 22, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $94.25 | +18.84% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $10.45 | +110.53% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $14.56 | +126.65% | 1 | May 21, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $34.77 | +230.74% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $3.09 | +94.17% | 1 | Mar 14, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $7.81 | +232.91% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $22 | $29.81 | -26.20% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $29.69 | -22.53% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $18.41 | +19.50% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.70 | +135.29% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $5.92 | +237.84% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $5.63 | +255.24% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $91.65 | +9.11% | 2 | Feb 8, 2023 |
IO Biotech
Oct 22, 2025
Maintains: Overweight
Price Target: $10 → $3
Current: $0.90
Upside: +232.96%
Scholar Rock Holding
Sep 24, 2025
Maintains: Overweight
Price Target: $52 → $51
Current: $29.88
Upside: +70.68%
argenx SE
Aug 26, 2025
Maintains: Overweight
Price Target: $750 → $820
Current: $836.39
Upside: -1.96%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $62 → $65
Current: $73.57
Upside: -11.65%
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $94.25
Upside: +18.84%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $10.45
Upside: +110.53%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $14.56
Upside: +126.65%
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $34.77
Upside: +230.74%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $3.09
Upside: +94.17%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $7.81
Upside: +232.91%
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $29.81
Upside: -26.20%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $29.69
Upside: -22.53%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $18.41
Upside: +19.50%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.70
Upside: +135.29%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $5.92
Upside: +237.84%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $5.63
Upside: +255.24%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $91.65
Upside: +9.11%